Status:
ACTIVE_NOT_RECRUITING
Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia
Lead Sponsor:
Children's Hospital Medical Center, Cincinnati
Conditions:
Fanconi Anemia
Squamous Cell Carcinoma
Eligibility:
All Genders
2+ years
Phase:
PHASE2
Brief Summary
Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid...
Detailed Description
Fanconi anemia (FA) is an autosomal recessive disease characterized by progressive bone marrow failure, variable congenital abnormalities and a predisposition to malignancy, particularly acute myeloid...
Eligibility Criteria
Inclusion
- Diagnosis of FA
- Able to take enteral medication
- Patients ≥2 years
Exclusion
- Renal failure requiring dialysis
- Total bilirubin \>3 mg/dl and/or SGPT \>200 at time of enrollment
- Patients receiving digoxin therapy, who are unable to discontinue either treatment due to medical reasons
- Patients who are pregnant or breastfeeding or are at risk of pregnancy or fathering a baby and are unable to use acceptable methods of birth control during the length of the study
- Patients who have received quercetin supplementation or other antioxidants within the last 30 days
- Patients receiving radiation therapy, chemotherapy or immunotherapy for treatment of SCC.
Key Trial Info
Start Date :
May 8 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2026
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT03476330
Start Date
May 8 2018
End Date
March 1 2026
Last Update
April 27 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States, 45229